Burning Rock Reports Second Quarter 2024 Financial Results
22 août 2024 23h59 HE
|
Burning Rock Biotech Limited
Burning Rock Reports Second Quarter 2024 Financial Results
Autologous Cell Therapy Market Estimated to Grow USD 34.7 Billion by 2027, Rising at a 18.1% CAGR- Transparency Market Research, Inc.
21 août 2024 11h09 HE
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. , Aug. 21, 2024 (GLOBE NEWSWIRE) -- According to Transparency Market Research (TMR), the global autologous cell therapy market...
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
20 août 2024 08h30 HE
|
AIM ImmunoTech Inc.
Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Additional commentary published discussing the potential of Ampligen and...
Burning Rock Biotech Limited Announces Expected Delisting of American Depositary Shares
19 août 2024 02h21 HE
|
Burning Rock Biotech Limited
Burning Rock Biotech Limited Announces Expected Delisting of American Depositary Shares
Home Healthcare Market to Reach $760.2 Billion, Globally, by 2033 at 10.5% CAGR: Allied Market Research
16 août 2024 10h11 HE
|
Allied Analytics LLP
Wilmington, Delaware, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Home Healthcare Market by Product and Service (Equipment, Software, and Services),...
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
16 août 2024 07h00 HE
|
AIM ImmunoTech Inc.
– Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications – Company to host conference call and webcast today, August...
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
15 août 2024 07h00 HE
|
TransCode Therapeutics, Inc.
TransCode Therapeutics Announces Phase 1 Clinical Trial Initiation
Turnstone Biologics Corp. Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
14 août 2024 16h05 HE
|
Turnstone Biologics Corp.
Turnstone reports second quarter 2024 financial results and provides recent business highlights
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
14 août 2024 16h01 HE
|
Turnstone Biologics Corp.
ORR of 25% and 50% DCR observed in first four evaluable patients treated with TIDAL-01 with advanced CRC
AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast
13 août 2024 09h05 HE
|
AIM ImmunoTech Inc.
OCALA, Fla., Aug. 13, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss...